1.540EUR0.00%Mkt Cap: 55.31M EURP/E: —Last update: 2026-05-14
Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients in Spain and the rest of European Union countries. It offers molecular diagnostics, such as mutation analysis in tissue …
Industry Peers
Diagnostics & Researchloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)Infinity
PEG—
P/B2.60
P/S3.31
EV/EBITDA-22.28
EV/Revenue3.47
EPS (TTM)-0.10
EPS (Forward)0.00
Cash Flow & Leverage
FCF Yield-1.56%
FCF Margin-5.17%
Operating CF-2.52M EUR
CapEx (TTM)472.49K EUR
Net Debt/EBITDA-0.78
Net Debt2.04M EUR
Technical
SMA 501.662 (-7.3%)
SMA 2001.692 (-9.0%)
Beta-0.02
S&P 52W Chg24.23%
Avg Vol (30d)1.11K
Avg Vol (10d)1.04K
Technical Indicators
RSI (14)21.1
MACD-0.0393
MACD Signal-0.0282
MACD Hist.-0.0111
BB Upper1.765 EUR
BB Middle1.627 EUR
BB Lower1.490 EUR
BB Width16.86%
ATR (14)0.0237 EUR
Vol Ratio (20d)0.09x
52W Range
1.5400% of range1.750
52W High1.750 EUR
52W Low1.540 EUR
Profitability
Gross Margin99.28%
EBITDA Margin-15.55%
Profit Margin-24.76%
Oper. Margin-20.63%
ROE-16.88%
ROA-11.20%
Revenue Growth139.70%
Earnings Growth—
Balance Sheet
Debt/Equity0.27
Current Ratio1.78
Quick Ratio1.47
Book Value/Sh0.5930 EUR
Cash/Share0.0520 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.35.91M
Float10.87M
Insiders69.32%
Institutions0.00%
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Company
Market Cap55.31M EUR
Enterprise Value57.99M EUR
Revenue (TTM)16.73M EUR
Gross Profit14.42M EUR
Net Income (TTM)-3.60M EUR
Revenue/Share0.4660 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2024
Employees159
Last Price1.540 EUR
CountryES
SectorHealthcare
IndustryDiagnostics & Research
ISIN—